What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Targeted therapy attacks a cancer-related molecule or signal; immunotherapy uses or changes immune activity so the body can recognize and attack cancer. Those are the primary distinctions, but the labels are broad. Some targeted medicines recruit immune cells, and different immunotherapies work in very different ways. A treatment’s name alone cannot tell you whether it is appropriate, effective, or safer for a particular person.
The useful comparison is between the specific medicine, the cancer’s features, the evidence for that use, and the patient’s health and treatment history. Biomarker testing can help identify options, but a matching result is not a promise that treatment will work.
As an Amazon Associate I earn from qualifying purchases.
What is the basic difference?
| Question | Targeted therapy | Immunotherapy |
|---|---|---|
| Primary action | Blocks or disrupts a selected protein, mutation, pathway, or other cancer-associated feature that helps cells grow, divide, survive, or spread. | Activates, releases, redirects, or supplies immune activity to help recognize and attack cancer. |
| Typical selection clue | A tumor has the molecular target that the drug is designed to affect. | The cancer has features, such as certain proteins or mutation patterns, that may make an immune approach relevant; some treatments do not require a known biomarker. |
| How benefit is evaluated | Imaging, examinations, laboratory results, symptoms, and sometimes a molecular test showing that the target remains present. | The same clinical assessments, interpreted with awareness that immune responses can have unusual timing and that inflammation can affect scans. |
| Main safety concern | The drug can affect healthy cells that share the target or rely on a related pathway. | An activated immune system can attack healthy tissues as well as cancer. |
| Can resistance occur? | Yes. The cancer may lack the target from the start or acquire changes that bypass the drug or alter the target. | Yes. Some tumors avoid immune recognition, suppress immune activity, or evolve after an initial response. |
These are categories, not two completely separate boxes. A monoclonal antibody used as a targeted treatment can block a growth signal, mark a cancer cell for immune destruction, or carry a toxic payload to a cell bearing the target. In that sense, a targeted treatment may involve the immune system even though its defining feature is the selected target. “Immunotherapy” is also an umbrella term: an immune checkpoint inhibitor and a cell-based treatment change immunity through different mechanisms and have different monitoring needs.
Recommended Free Tools
How targeted therapy works
Finding and blocking a cancer dependency
Cancer cells often carry changes or produce unusually high amounts of proteins that control growth, division, repair, blood-vessel formation, or survival. A targeted drug is designed to interfere with one of those features. The target may be a mutated gene product, a receptor on the cell surface, an enzyme inside the cell, or a signal that cancer cells use to communicate.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Small-molecule targeted drugs are able to enter cells and act on internal targets. Monoclonal antibodies are larger laboratory-made proteins that bind selected targets on the outside of cells or in the tissue around them. Depending on the medicine, an antibody can block a growth message, flag a cancer cell for immune attack, or deliver a toxin or radioactive substance to cells carrying the target. The actual drug mechanism matters more than the broad label.
Why the target matters
A targeted drug generally has a plausible chance of helping only when the cancer has the feature the drug is designed to affect, although the presence of a target does not ensure benefit. A tumor can contain the target in too few cells, use an alternate growth pathway, or have other biological characteristics that prevent a response. The cancer may also change during treatment, allowing it to grow despite continued dosing.
Examples of effects and limitations
Depending on the pathway involved, targeted medicines can produce effects such as skin or nail changes, diarrhea, high blood pressure, liver or other organ problems, or changes in blood counts. These are examples across the category, not a prediction for a particular drug. The prescribing information for the exact medicine and the oncology team’s instructions determine which symptoms require urgent attention.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →How immunotherapy works
Releasing immune brakes
Some cancers use checkpoint signals to make immune cells stand down. Checkpoint inhibitors block those inhibitory interactions, allowing T cells or other immune components to remain active against tumor cells. This does not mean every tumor will be recognized or that an immune response will be strong enough to shrink it.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Supplying or redirecting immune cells
Other immunotherapies provide immune-stimulating substances, antibodies that recruit immune activity, or cells prepared to recognize cancer. Cell-based approaches can involve collecting immune cells, modifying or expanding them, and returning them to the patient. Each approach has its own eligibility rules, preparation, possible complications, and follow-up.
Why immunotherapy is not one treatment
The word “immunotherapy” covers multiple families of treatment. A checkpoint inhibitor, a cell-based therapy, and an immune-stimulating drug do not have identical response patterns or side effects. Even within one family, the dose, combination, cancer type, and treatment sequence can change the balance of benefit and risk.
Does biomarker testing matter?
What a biomarker can show
The National Cancer Institute states: “Some cancer treatments, including targeted therapies and immunotherapies, may only work for people whose cancers have certain biomarkers.” A biomarker is a measurable feature of a tumor or, in some cases, the patient that can provide information about diagnosis, prognosis, or treatment selection.
For targeted therapy, testing may look for the molecular change or protein that a drug is designed to affect. The NCI gives an EGFR gene change as an example: finding that change may make an EGFR inhibitor an option in the appropriate cancer setting. For immunotherapy, testing may assess features that can inform whether some checkpoint inhibitors or other immune treatments are reasonable options. The relevance of a result depends on the exact test, cancer type, stage, treatment line, and medicine.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
How testing is performed
Most biomarker tests use tumor tissue obtained during a biopsy or surgery. In some situations, a liquid biopsy analyzes tumor-related material circulating in blood. A tissue sample can be limited, degraded, or unrepresentative of every tumor site, while a blood test may fail to detect a feature that is present at a low level. The team may recommend one test, repeat testing, or a different specimen when the result does not fit the clinical picture.
What a result can and cannot authorize
A result can identify a possible approved treatment, suggest an off-label option, or support consideration of a clinical trial. It is not itself a prescription. The result also does not guarantee that the cancer will respond, that the benefit will last, or that the expected risks are acceptable for a particular patient. Biomarkers can change as cancer evolves, and testing does not provide a useful answer for every person.
Questions to ask about a test report
- What alteration, protein level, or other feature was detected, and in which sample?
- Is the result required for the proposed medicine, or does it only provide supporting information?
- Was the test validated for this cancer and treatment decision?
- Does the result correspond to an approved use, an off-label use, or a clinical trial?
- Could the biomarker differ in a recurrence or another tumor site?
How side effects differ
Targeted-treatment toxicities
Targeted drugs are selective, not perfectly selective. A protein that drives cancer may also be present in healthy tissue, or a normal organ may depend on the same pathway. As a result, side effects vary widely by medicine. Across targeted therapies, clinicians may monitor skin and nail changes, diarrhea, blood pressure, liver function, heart function, blood counts, or other organ effects.
The schedule matters. Some effects begin soon after treatment; others appear after cumulative exposure or when two medicines are combined. Dose changes, treatment pauses, supportive medicines, or switching therapy may be considered, but the correct response depends on the drug and the severity of the problem. Do not stop a prescribed treatment without contacting the treating team.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Immune-related side effects
Immunotherapy can cause inflammation when activated immune cells affect healthy organs. Possible sites include the skin, bowel, liver, lungs, endocrine glands, kidneys, nerves, heart, or other tissues. Symptoms can be mild or life-threatening, and they may occur during treatment or after a dose has ended. The risk varies with the immunotherapy, dose, combinations, cancer context, and the patient’s health.
New or worsening diarrhea, severe abdominal pain, cough or shortness of breath, yellowing of the skin, unusual fatigue, severe rash, confusion, weakness, changes in urination, or other unexpected symptoms should be reported according to the team’s instructions. Some immune-related effects require prompt evaluation and medicines that suppress inflammation. The patient information for the actual medicine gives the most reliable warning list and contact guidance.
Neither category is automatically gentler
It is inaccurate to call all targeted therapy mild or all immunotherapy dangerous. A targeted drug can cause serious organ toxicity, and an immune-related reaction can be severe even when the treatment initially seemed easy to tolerate. Conversely, many people receive either category without a serious complication. Risk is treatment-specific and patient-specific, so monitoring plans should be discussed before the first dose.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchResponse, resistance, and what happens if treatment stops working
Assessing response
The oncology team may combine scans, physical examinations, symptoms, blood tests, and other disease-specific measurements to judge whether treatment is helping. A biomarker result can support the rationale for treatment but cannot substitute for follow-up. The timing and interpretation of scans are set by the treatment protocol and the cancer’s behavior.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Why targeted therapy can fail
If the intended target is absent, the drug may have little or no effect. Even when the tumor initially shrinks, cancer cells can acquire additional changes, activate a bypass pathway, or alter the target so the medicine no longer binds effectively. A later biopsy or liquid biopsy may sometimes identify a resistance mechanism, but testing is not informative in every case.
Why immunotherapy can fail
Some tumors prevent immune cells from entering, create an immunosuppressive environment, or fail to display features that immune cells can recognize. Other cancers evolve after an initial response and become resistant. Response varies considerably among patients, and there is no universal response-rate winner between the two categories across all cancers.
Options after progression
If the cancer grows or side effects become unacceptable, the team may review whether the diagnosis or biomarker should be reassessed, change the dose or schedule, switch to another treatment class, combine treatments, or consider a clinical trial. The available choices depend on cancer type and subtype, where it has spread, previous therapies, current organ function, other medicines, and the person’s goals.
Free tools Windows power users keep installed
One-click scans. No signup required.
How doctors choose between the categories
A category-level comparison cannot select treatment. The decision usually integrates the following factors:
- Cancer identity and extent: the organ of origin, molecular subtype, stage, spread pattern, and whether the disease is newly diagnosed, recurrent, or resistant.
- Evidence for the exact use: results from studies and regulatory approvals for that medicine in that cancer and treatment setting.
- Biomarker information: whether a required or informative feature is present, how reliable the test is, and what uncertainty remains.
- Previous treatment: earlier drugs, radiation, surgery, response duration, resistance findings, and lingering toxicities.
- Health context: organ function, autoimmune disease, transplant history, infections, other medicines, pregnancy potential, and ability to attend monitoring visits.
- Practical and personal priorities: infusion or pill schedules, travel, support at home, symptom tolerance, and the patient’s goals.
Two people with the same broad cancer type may therefore receive different approaches. A treatment that is reasonable after one biomarker result or treatment history may be unsuitable after another. The care team weighs expected benefit against known and uncertain risks rather than choosing based on the category name.
A practical comparison for an oncology appointment
Use the following framework to compare the actual options offered to you:
- Name the treatment. Ask for the generic name, whether it is a small molecule, antibody, checkpoint inhibitor, cell-based treatment, or combination, and how it acts in your cancer.
- Identify the decision-driving evidence. Ask which biomarker or clinical feature supports the option, whether it is required, and how the test was performed.
- Clarify expected benefit. Discuss the goal—shrinkage, disease control, symptom relief, preventing recurrence, or another endpoint—and how success will be measured.
- Map the safety plan. Ask which blood tests, scans, examinations, and specialist reviews are needed; when side effects usually occur; and which symptoms require a same-day call or emergency care.
- Review alternatives. Ask what other approved treatments, combinations, supportive-care approaches, or clinical trials fit the diagnosis and treatment history.
- Plan for nonresponse. Ask when the first assessment will occur and what could be considered if the cancer progresses or the medicine must be stopped.
Questions worth taking to the care team
- What is the exact name of the treatment, and what does it target or change in my cancer?
- Which biomarker results support or rule out this option, and what are the limits of those results?
- What benefits and risks are known for my diagnosis, stage, and prior treatments?
- Which symptoms should prompt a call, whom should I contact after hours, and when should I seek emergency care?
- How will you tell whether the treatment is working, and when will that assessment occur?
- What could be considered if the cancer does not respond, later progresses, or side effects become unacceptable?
Bottom line for the comparison
Targeted therapy is defined mainly by the cancer feature it attacks; immunotherapy is defined mainly by the way it engages or changes immune activity. Biomarker testing can make either type more relevant, but a result is not a guarantee. Both categories contain treatments with distinct benefits, toxicities, monitoring requirements, and resistance patterns. The appropriate choice comes from the specific medicine’s evidence, the cancer’s current biology, and the patient’s health and goals—not from assuming that one label is inherently better or safer.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
